Using PARP Inhibitors in Frontline Maintenance Therapy of Ovarian Cancer

January 20, 2021
Thomas Herzog, MD

Thomas Herzog, MD, provides insight on key clinical trials and the use of PARP inhibition in frontline maintenance therapy for ovarian cancer.

Related Content:

Clinical ConsultOvarian Cancer Clincal ConsultOvarian Cancer
FDA Grants Fast Track Designation to GEN-1 Immunotherapy for Treatment of Advanced Ovarian Cancer
Niraparib Maintenance Therapy Shows Promise for Chinese Patients With Platinum-Sensitive, Recurrent Ovarian Cancer
Pooled Prevalence, Risk Factors of Chemotherapy-Related VTE in Ovarian Cancer Are Revealed